A massive new analysis suggests that a single blood draw that measures the phosphorylated tau protein p‑tau217 can estimate an older adult’s odds of developing cognitive problems over roughly the next five to ten years. University of Wisconsin investigators, including contributors to the Wisconsin Registry for Alzheimer’s Prevention (WRAP), took part in the multicohort study, and Dr. Jessica Caldwell broke down the findings on FOX6’s Wisconsin Live Desk.
What the JAMA study found
The pooled analysis drew on data from 2,684 cognitively unimpaired adults across six research cohorts. It found that people who started out with higher levels of plasma p‑tau217 showed faster cognitive decline and a higher chance of progressing to clinical impairment over time.
According to JAMA, participants with “very high” p‑tau217, defined as more than 2.5 standard deviations above the mean, had an estimated 38% absolute risk of developing mild cognitive impairment or dementia within five years. The projected risk over ten years was even higher, although estimates that far out were less certain.
Local researchers weigh in
Dr. Jessica Caldwell, a multi‑principal investigator with WRAP, joined Wisconsin Live Desk to explain why this blood marker matters for the research world and for enrolling volunteers into prevention trials. As reported by FOX6, she highlighted the test’s promise as a screening tool to find people at higher risk who might qualify for studies, while stressing that a single blood test result is not the same thing as a clinical diagnosis.
How the test works and where it falls short
Plasma p‑tau217 is a blood measure that reflects tau changes in the brain and lines up closely with PET scan and cerebrospinal fluid markers. In everyday terms, it is a strong signal but not a crystal ball. Experts emphasize that it gives a probability of future problems rather than a simple yes or no answer.
The study authors and an accompanying commentary say the results strengthen models that predict who is most likely to decline and help refine how trial slots are allocated. At the same time, they underline the need to test p‑tau217 in broader, more diverse, community‑based populations before anyone treats it as a routine tool in everyday practice; see JAMA.
What this means locally
For people in Milwaukee and across Wisconsin, the findings build on years of local brain health research. WRAP has followed volunteers for decades and supplies samples and data to national biomarker projects. The Wisconsin Registry for Alzheimer’s Prevention and the Wisconsin Alzheimer’s Institute continue to host outreach events and information sessions that share updates from studies like this one and outline ways residents can get involved.
Bottom line
Researchers say a single p‑tau217 blood test could speed up enrollment into Alzheimer’s prevention trials and sharpen probabilistic counseling about future risk, but it does not yet change how doctors typically diagnose or treat patients. Analyses from research cohorts and clinical trials indicate that pairing plasma p‑tau217 with cognitive testing and genetic information makes predictions of decline more accurate, which is expected to matter both for future trial design and for clinicians planning long‑term follow‑up; see results in Alzheimer's & Dementia.
